609: CH Systemic Lupus Erythematosus: Novel Therapies for SLE

Community Speaker(s)

• AA

  Anca Askanase, MD, MPH

  Director
  Columbia University Medical Center
  New York, NY, United States

  Disclosure(s): Amgen: Advisor or Review Panel Member (Ongoing); AstraZeneca: Advisor or Review Panel Member (Ongoing), Grant/Research Support (Ongoing); Aurinia: Advisor or Review Panel Member (Ongoing); Eli Lilly: Grant/Research Support (Ongoing); GlaxoSmithKlein(GSK): Advisor or Review Panel Member (Ongoing); Idorsia: Grant/Research Support (Ongoing); Janssen: Grant/Research Support (Ongoing); Pfizer: Grant/Research Support (Ongoing); UCB: Grant/Research Support (Ongoing)

Hub Host(s)

• 

  Karen Costenbader, MD, MPH

  Brigham and Women's Hospital/ Harvard Medical School
  BOSTON, MA, United States

  Disclosure information not submitted.
• DI

  David Isenberg, MD, FRCP

  University College London
  London, United Kingdom

  Disclosure information not submitted.

Community Speaker(s)

• 

  Georg Schett, MD

  Friedrich-Alexander-Universität Erlangen-Nürnberg
  Erlangen, Germany

  Disclosure(s): No financial relationships with ineligible companies to disclose
• 

  Richard Furie, MD

  Chief of the Division of Rheumatology
  Northwell Health
  Manhasset, NY, NY, United States

  Disclosure(s): AstraZeneca: Consultant (Ongoing), Grant/Research Support (Ongoing); Biogen: Consultant (Ongoing), Grant/Research Support (Ongoing)

Discussion: Novel Therapies in the SLE Pipeline
Viewpoints: DOACS in SLE APS by Anca Askanase, MD